NASDAQ: ACCDAccolade Inc Stock
$9.21+0.08 (+0.88%)
Updated Apr 22, 2024
ACCD Price
$9.21
Fair Value Price
N/A
Market Cap
$712.92M
52 Week Low
$6.33
52 Week High
$17.01
P/E
-5.72x
P/B
1.64x
P/S
1.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$388.49M
Earnings
-$122.73M
Gross Margin
44.6%
Operating Margin
-32.78%
Profit Margin
-31.6%
Debt to Equity
0.81
Operating Cash Flow
-$25M
Beta
2.36
Next Earnings
Apr 25, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ACCD Overview
Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACCD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACCD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ACCD is good value based on its book value relative to its share price (1.64x), compared to the US Health Information Services industry average (3.36x)
P/B vs Industry Valuation
ACCD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ACCD due diligence checks available for Premium users.
Be the first to know about important ACCD news, forecast changes, insider trades & much more!
ACCD News
Valuation
ACCD fair value
Fair Value of ACCD stock based on Discounted Cash Flow (DCF)
Price
$9.21
Fair Value
$13.83
Undervalued by
33.40%
ACCD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACCD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.72x
Industry
73.71x
Market
41x
ACCD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.64x
Industry
3.36x
ACCD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACCD's financial health
Profit margin
Revenue
$99.4M
Net Income
-$21.1M
Profit Margin
-21.2%
ACCD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ACCD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$785.5M
Liabilities
$350.8M
Debt to equity
0.81
ACCD's short-term assets ($272.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACCD's short-term assets ($272.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACCD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$5.2M
Investing
-$3.7M
Financing
-$63.7M
ACCD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACCD vs Health Information Service Stocks
Accolade Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.